RVL Pharmaceuticals Upneeq Wins 2021 MedTech Breakthrough Award
RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced that its ptosis drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.
Upneeq provides patients and eye care providers with a safe and convenient non-surgical option to treat adults with acquired blepharoptosis (ptosis). The FDA-approved eye drop is the first and only therapeutic approved for the condition which previously required a surgical procedure. Upneeq is a safe and effective, first-in-class treatment for acquired ptosis and it demonstrated statistically significant improvements compared to placebo in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy studies. The medication is composed of oxymetazoline hydrochloride ophthalmic solution, 0.1%.
“This eye drop represents a true therapeutic innovation, empowering eye care specialists with a safe and convenient non-surgical option to treat their patients who have ptosis,” James Johnson, managing director, MedTech Breakthrough, said in a company news release. “We extend our sincere congratulations to RVL Pharmaceuticals for winning our ‘Best New Technology Solution for Drug Delivery’ award and, more importantly, improving the lives of millions of patients through the use of their first in class Upneeq solution.”
The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Robotics, Clinical Administration, Telehealth, Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,850 nominations from over 17 different countries throughout the world.
“Low-lying lids have both visual consequences, as the abnormal drooping of the upper eyelid can lead to vision impairment, and cause cosmetic concerns for the sufferer,” said Brian Markison, CEO of Osmotica Pharmaceuticals. “Due to the lack of an approved non-surgical treatment, ptosis has been often underdiagnosed or overlooked. We believe Upneeq has the potential to address a significant unmet need in ptosis therapy and we are grateful to receive this 2021 MedTech Breakthrough Award in recognition of our hard work and innovation in this space.”